Skip to content

Cronos 集团

US · CRON #3133 按市值排名 上市于 1970
3.21 +0.01 +0.31%
实时 - 追踪5344个代码 - 心跳于68秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.13 高于历史水平 第96百分位
5年平均 0.83 · 在Drug Manufacturers - Specialty & Generic中排名第27/70
市盈率 17.29 高于历史水平 第87百分位
5年平均 -5.23 · 前瞻 24.39 · 在Drug Manufacturers - Specialty & Generic中排名第11/25
市销率 6.76 低于历史水平 第21百分位
5年平均 10.48 · 前瞻 6.70 · 在Drug Manufacturers - Specialty & Generic中排名第62/80

同业对比 Drug Manufacturers - Specialty & Generic

公司 市值 市盈率(TTM) 市净率 股息率
Cronos 集团 (CRON) 1.18B 16.89 1.11 0.00%
Takeda Pharmaceutical (TAK) 62.84B -59.43 1.31 3.04%
Teva Pharmaceutical Industries (TEVA) 48.40B 69.17 6.24 0.00%
Haleon (HLN) 44.55B 21.06 2.05 1.88%
Zoetis (ZTS) 32.80B 12.95 10.42 2.60%
United Therapeutics (UTHR) 22.87B 19.10 3.57 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值3.62 经济护城河None 不确定性Medium

当前股价低于晨星合理价值估算12.6%。

合理价值

Cronos Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $3.61 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 89.4%, which lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 14.6%, a core component of profitability, sits in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

Cronos 集团 讨论区 0 条评论

发表评论